Repurposing EGFR Inhibitor Utility in Colorectal Cancer in Mutant APC and TP53 Subpopulations.
Mingli YangMichael J SchellAndrey LobodaMichael NebozhynJiannong LiJamie K TeerW Jack PledgerTimothy J YeatmanPublished in: Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology (2019)
These findings, if further validated through clinical trials, could also expand the utility of EGFRi therapies that are currently underutilized.